アジア太平洋の臨床バイオマーカー市場： 分析・予測 (2023-2033年)

アジア太平洋の臨床バイオマーカーの市場規模は、2023年の32億8,000万米ドルから、予測期間中はCAGR 9.27%で推移し、2033年には79億5,000万米ドルに達すると予測されています。

アジア太平洋の臨床バイオマーカー市場は、バイオテクノロジーの進歩、医療支出の増加、個別化医療への関心の高まりなどを背景に急速に拡大しています。中国、日本、インドなどの国々が最前線にあり、研究開発への多額の投資と活発な臨床試験活動が行われています。癌や心血管系疾患などの慢性疾患の有病率が上昇していることが、早期診断ツールや標的治療に対する需要を促進しています。政府の取り組みや学術機関とバイオ医薬品企業との協力関係も市場成長をさらに後押ししています。また、次世代シーケンシングやバイオインフォマティクスなどの先端技術の統合が、新規バイオマーカーの同定と検証を強化し、アジア太平洋地域を臨床バイオマーカーの展望における重要な拠点にしています。

当レポートでは、アジア太平洋の臨床バイオマーカーの市場を調査し、市場および技術の動向、市場影響因子の分析、市場規模の推移・予測、主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

第1章 市場

第2章 市場の範囲

第3章 調査手法

第4章 市場概要

• 精密医療における臨床バイオマーカーアプローチ
• 臨床バイオマーカーの市場規模の可能性
• COVID-19が臨床バイオマーカー市場に与える影響
• 市場動向
  • バイオマーカー発見におけるAIの統合
  • 精密医療におけるバイオマーカーの利用の増加
  • 臨床バイオマーカー検査に使用されている技術
  • 臨床バイオマーカーの発見により病気の早期診断が可能に

第5章 地域

• 概要
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • その他

第6章 市場：企業プロファイル

• 概要
• BGI
• Novogene Co., Ltd.

List of Figures

• Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
• Figure 2: Asia-Pacific Clinical Biomarkers Market Research Methodology
• Figure 3: Primary Research Methodology
• Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 5: Top-Down Approach (Segment-Wise Analysis)
• Figure 6: Biomarkers Used in Various Clinical Areas
• Figure 7: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
• Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
• Figure 10: Use of Clinical Biomarkers in Personalized Medicine
• Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
• Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
• Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
• Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
• Figure 15: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 16: Asia-Pacific Clinical Biomarkers Market (by Country), $Billion, 2022-2033
• Figure 17: Asia-Pacific: Market Dynamics
• Figure 18: China Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 19: India Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 20: Japan Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 21: South Korea Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 22: Australia Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 23: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
• Figure 24: Total Number of Companies Profiled
• Figure 25: BGI: Service Portfolio
• Figure 26: Novogene Co., Ltd.: Service Portfolio

List of Tables

• Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
• Table 2: List of Product/Service Offered and its Technology

Introduction to Asia-Pacific Clinical Biomarkers Market

The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.

Market Introduction

The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.

Market Segmentation:

Segmentation 1: by Country

• China
• India
• Japan
• South Korea
• Australia
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are

• BGI
• Novogene Co., Ltd.

Table of Contents

Executive Summary

1 Market

2 Market Scope

• 2.1 Key Questions Answered in the Report

3 Research Methodology

• 3.1 Data Sources
  • 3.1.1 Primary Data Source
  • 3.1.2 Secondary Data Sources
    • 3.1.2.1 Open Sources
• 3.2 Market Estimation Model
• 3.3 Criteria for Company Profiling

4 Market Overview

• 4.1 Introduction
• 4.2 Clinical Biomarkers Approaches in Precision Medicine
• 4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
• 4.4 COVID-19 Impact on Clinical Biomarkers Market
  • 4.4.1 COVID-19 Impact on Market Size
• 4.5 Market Trends
  • 4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
  • 4.5.2 Increasing Biomarkers Usage in Precision Medicine
  • 4.5.3 Technologies Being Used in Clinical Biomarker Testing
  • 4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region

• 5.1 Overview
• 5.2 Asia-Pacific
  • 5.2.1 China
  • 5.2.2 India
  • 5.2.3 Japan
  • 5.2.4 South Korea
  • 5.2.5 Australia
  • 5.2.6 Rest-of-Asia-Pacific

6 Market - Company Profiles

• 6.1 Overview
• 6.2 BGI
  • 6.2.1 Company Overview
  • 6.2.2 Role of BGI in the Clinical Biomarkers Market
  • 6.2.3 Corporate Strategies
    • 6.2.3.1 Product Launch
  • 6.2.4 Analyst's Perspective
• 6.3 Novogene Co., Ltd.
  • 6.3.1 Company Overview
  • 6.3.2 Role of Novogene Co., Ltd. in the Clinical Biomarkers Market
  • 6.3.3 Analyst's Perspective